Tomas Jansson Group
Future medical imaging technology moves in the direction of molecular imaging where a contrast agent has been functionalized with tumor/tissue specific targeting agents (i.e. antibodies, affibodies, peptides, aptamers). Thus the contrast particle binds specifically to e.g. tumor tissue and can be enriched there. In other words, what is probed is the molecular abnormality that is the basis of the d
https://www.bme.lth.se/en/research/ultrasound/tomas-jansson-group - 2026-07-17
